First test of gene therapy for rare form of autism is underwaynews2026-02-23T14:00:16+00:00February 23rd, 2026|Endpoints News|
How a closet full of EKG machines illustrates pharma’s clinical trial cost problemnews2026-02-11T15:00:30+00:00February 11th, 2026|Endpoints News|
Hengrui blazes trail as Chinese drugmakers aspire to go multinationalnews2026-01-28T15:00:06+00:00January 28th, 2026|Endpoints News|
As gene editing tools multiply, the hunt for the final technology continuesnews2025-12-29T17:02:50+00:00December 29th, 2025|Endpoints News|
Biopharma’s winners and losers of 2025news2025-12-18T16:20:28+00:00December 18th, 2025|Endpoints News|
AI biotech preview of 2026: Clinic takes center stagenews2025-12-17T14:00:16+00:00December 17th, 2025|Endpoints News|
Western genetic medicine makers turn to Chinese investigator-initiated trialsnews2025-12-15T12:30:18+00:00December 15th, 2025|Endpoints News|
As approval date looms, Cytokinetics gears up for David-and-Goliath battle with Bristol Myersnews2025-12-02T14:00:46+00:00December 2nd, 2025|Endpoints News|
Are recent strides in neurology R&D enough to make it a hot M&A target?news2025-10-23T14:00:48+00:00October 23rd, 2025|Endpoints News|
Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer?news2025-10-16T14:47:42+00:00October 16th, 2025|Endpoints News|
